SMAD4 and neoplasm: This transition is usually associated with mutations or deletions in TGF-β receptors (e.g., TGFβRII) or Smad4, leading to tumor cell migration and invasion, dysregulation of TME, and promotion of tumor immune escape and angiogenesis [52,53].